Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argos's Arcelisâ¢ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks